Retatrutide and Lean Mass: Trial Evidence

The study behind the claim

The 2025 body-composition report is a substudy of a phase 2 trial in adults with type 2 diabetes. Its prespecified primary endpoint was the percentage change in total fat mass at 36 weeks, measured with dual-energy X-ray absorptiometry, or DXA. It was not primarily designed to test strength or physical performance ^[1].

The parent trial randomized 281 participants and compared retatrutide with placebo and dulaglutide. Its primary endpoint was HbA1c change at 24 weeks; weight change was among the secondary outcomes ^[2]. The body-composition paper therefore answers an additional question within an existing trial, rather than providing a second independent randomized population.

The denominator narrows

Of the 281 participants in the main study, 189 entered the body-composition substudy. There were 155 baseline DXA scans, and 103 participants completed treatment with both baseline and week-36 scans. The efficacy analysis used available on-treatment scans before treatment discontinuation ^[1].

Those numbers matter when interpreting a strong fat-loss headline. The paired-scan completers are a subset of the original randomized population. Their results should not be described as a measurement of body composition in every participant or every person who begins treatment.

Missing follow-up measurements do not automatically invalidate a study, but they make the analysis population part of the finding. A reliable summary states both the result and whose measurements produced it.

Fat loss is not zero lean-mass loss

The investigators found greater reductions in total fat mass with several retatrutide groups than with placebo or dulaglutide. Their interpretation was that the proportion of lost weight coming from lean mass was similar to that seen with other obesity treatments ^[1].

That statement does not mean lean mass remained unchanged. Nor does it establish that retatrutide preserves muscle better than semaglutide or tirzepatide: neither of those drugs was a randomized comparison group in this substudy ^{[1, 2]}.

DXA-derived lean mass and muscle function are also different outcomes. The primary endpoint here was fat mass. A claim of preserved strength would need an appropriate strength measurement and comparison; it cannot be inferred from the scale or from the proportion of weight loss attributed to fat.

Newer weight trials answer other questions

The published phase 3 TRIUMPH-1 trial randomized 2,339 adults with obesity without diabetes and followed treatment for 80 weeks. Its reported treatment-regimen analysis showed a mean weight reduction of 25.0 percent in the highest-strength group versus 3.9 percent with placebo ^[3].

That larger trial strengthens the evidence about weight change in its studied population. It does not enlarge the paired-DXA sample in the earlier diabetes substudy or convert a weight result into a muscle-function result. The populations, follow-up and endpoints should remain visible when the studies are discussed together.

Headline percentages can also differ according to how a study handles treatment discontinuation and other events. A sponsor headline from one analysis should not be silently substituted for a publication’s treatment-regimen estimate.

The practical reading

The body-composition findings are compatible with meaningful fat reduction while some lean mass is also lost. They do not support a promise that a person can lose substantial weight without any lean-tissue change, or that an investigational product is safe for unsupervised use.

The studies concerned defined trial populations and controlled study products ^{[1, 2, 3]}. A seller’s research-use-only vial is not validated by these results. The retatrutide monograph keeps the regulatory and clinical evidence separate; this review provides neither a self-treatment protocol nor a comparison of home dosing strategies.

Elsewhere in this index